Nebilet Plus H (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide / Nebivolol, the active ingredient in Nebilet Plus H, is a beta‑blocker / thiazide diuretic presented as a tablet for oral use. It treats hypertension in adults, often as part of combination therapy.

GNH USA supplies Nebilet Plus H as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet Plus H is indicated for the management of hypertension, a condition characterized by elevated arterial blood pressure.

- Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk. - Stage 1 hypertension: provides blood‑pressure control when lifestyle measures are insufficient. - Stage 2 hypertension: used as part of combination therapy to achieve target pressures.

Adverse reactions may occur with Nebilet Plus H and are reported in clinical use.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute renal impairment - Hyperkalemia or hyponatremia - Allergic reactions (rash, angioedema) - Pancreatitis - Cardiac arrhythmias

Before prescribing Nebilet Plus H, clinicians should consider several safety aspects.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Electrolyte assessment: monitor sodium and potassium levels during therapy. - Renal function: evaluate baseline and periodic kidney function. - Diabetes management: observe potential rise in blood‑glucose levels. - Pregnancy and lactation: use only if clearly indicated after risk‑benefit analysis. - Store at ambient temperature: keep in the original pack, protect from moisture.

Nebilet Plus H can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Other antihypertensives: may cause additive hypotensive effects. - Lithium: increased risk of lithium toxicity. - NSAIDs: may blunt diuretic efficacy and affect renal function. - Potassium‑sparing diuretics: heightened risk of hyperkalemia. - CYP2D6 inhibitors: can raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive blood‑pressure lowering. - Antidiabetic agents: thiazides may impair glucose control. - Beta‑agonists: may reduce nebivolol's beta‑blocking action. - Alcohol: can enhance hypotensive response.